<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03293615</url>
  </required_header>
  <id_info>
    <org_study_id>6431</org_study_id>
    <nct_id>NCT03293615</nct_id>
  </id_info>
  <brief_title>Exercise Capacity of Patients With Dermatomyosis</brief_title>
  <acronym>MIDE</acronym>
  <official_title>Exercise Capacity of Patients With Dermatomyosisthe Role of Muscle Mitochondria and Reactive Oxygen Species</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dermatomyositis (DM) patients experience muscle weakness and low aerobic capacities, which
      are associated with poor health status and increased mortality. The origin of this muscle
      impairment remains unknown.

      The investigators hypothesize that mitochondria functioning is impaired in DM muscle and
      links with exercise capacities.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the capacity of muscle fibers to consume oxygen in the muscle of patients i) with DM, ii) with other inflammatory myopathy, iii) without neuromuscular disease.</measure>
    <time_frame>Baseline</time_frame>
    <description>This difference in mitochondrial breathing capacity in the muscle will be achieved by: Muscle biopsy</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Dermatomyositis</condition>
  <arm_group>
    <arm_group_label>Dermatomyositis (DM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with dermatomyositis according to ENMC criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-dermatomyositis inflammatory myopathies</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with other inflammatory myopathy than dermatomyositis according to ENMC criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No myopathy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients without myopathy on muscle biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>exploration</intervention_name>
    <description>Difference of the following parameters in patients i) with DM, ii) with another inflammatory myopathy iii) without neuromuscular disease.</description>
    <arm_group_label>Dermatomyositis (DM)</arm_group_label>
    <arm_group_label>Non-dermatomyositis inflammatory myopathies</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman or man&gt; 18 years,

          -  Signature of informed consent,

          -  Muscle biopsy for suspicion of recent inflammatory myopathy (&lt;6 months) or for
             exclusion of neuromuscular pathology.

        Prospectively, following the results of the muscle biopsy, the subjects will divided into
        three groups meeting the following criteria:

          -  &quot;DM&quot; group: DM according to the ENMC criteria;

          -  &quot;other inflammatory myopathy&quot; group: polymyositis, autoimmune necrotizing myopathy,
             non-specific myositis or inclusion myositis according to the ENMC criteria;

          -  Group &quot;no neuromuscular pathology&quot;: i) myalgia and / or intolerance to exercise and
             ii) normal neuromuscular examination, iii) no increase in blood creatine kinase level,
             iv) absence of electromyographic abnormality, v) histological Muscle mass.

        Exclusion Criteria:

          -  - Taking an immunomodulatory treatment within 6 months before inclusion,

          -  Paraneoplastic form of the disease,

          -  Presence of associated interstitial pneumonitis,

          -  Neuromuscular pathology different from inflammatory myopathy,

          -  Unbalanced cardiovascular disease,

          -  Impossibility of giving the subject informed information (subject in an emergency
             situation, difficulty in understanding the subject, ...),

          -  Subject under safeguard of justice,

          -  Subject under tutelage or under curators,

          -  Pregnancy (positive pregnancy test)

          -  Breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alain Meyer, MD</last_name>
    <phone>00333 6 76 95 31 67</phone>
    <email>alain.meyer1@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alain Alain, MD</last_name>
    <phone>00333 6 76 95 31 67</phone>
    <email>alain.meyer1@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2017</study_first_submitted>
  <study_first_submitted_qc>September 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatomyositis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

